Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI EBITDA Margin

EBITDA as a percentage of revenue.

Atai Beckley Inc.NASDAQ: ATAI

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to -2577.8%

EBITDA Margin was -2577.8% in Q2 FY2026, up 1203.8 pp from a year earlier. On a trailing-twelve-month basis it was -15185.0%, down 10544.1 pp year over year. Over 3 fiscal years it widened by 48335.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of -7024.8% for the fiscal year ending Dec 2026, up from -16084.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-2577.8%+526.5 pp QoQ
Last fiscal yearDec 2025
-16084.0%+31751.4 pp YoY
LTMJun 2026
-15185.0%-10544.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1203.8 pp-6629.3 pp-7833.1 pp
1 year+31751.4 pp+9059.3 pp-22692.1 pp
3 years+48335.3 pp+10222.9 pp-38112.4 pp
5 years+16077.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-16084.0%
Year-over-year change
+31751.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ATAI compares with its peers on the latest reported figures

  • ATAI's LTM Jun 2026 EBITDA Margin of -15185.0% is the lowest of the 7 companies compared; the peer median is -1046.8%.
  • Its year-over-year change of -10544.1 pp is the 6th highest of 7, against a peer median of +269.7 pp.
  • Over three fiscal years its change of +48335.3 pp compares with a peer median of -412.4 pp.
ATAI Competitors Peer median
EBITDA Margin for ATAI and competitors
Company Period LTM level YoY 3-year change
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-74.8% +669.1 pp—
NKTRNektar TherapeuticsLTM Jun 2026-246.2% -129.7 pp+103.8 pp
IMTXImmatics N.V.LTM Mar 2026-542.7% -539.6 pp-412.4 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-1550.9% +804.4 pp-7510.8 pp
RLAYRelay Therapeutics, Inc.LTM Jun 2026-2742.3% +927.4 pp+20440.0 pp
INBXInhibrx Biosciences, Inc.LTM Mar 2026-9007.0% -875818.5 pp-4455.7 pp
ATAIAtai Beckley Inc.LTM Jun 2026-15185.0% -10544.1 pp+48335.3 pp
ELVNEnliven Therapeutics, Inc.FY2025— ——
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
SANASana Biotechnology, Inc.FY2025— ——
Peer median (excluding ATAI) -1046.8%+269.7 pp-412.4 pp

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.